Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- White Paper Focuses on Different Economic Conditions between Generations
September 23, 2002
- Ortho Clinical Diagnostics: HCV Antigen Test Kits
September 23, 2002
- NEW PRODUCTS
September 23, 2002
- Gastric Cancer Discovered in 0.29% of Individuals by Endoscopy
September 23, 2002
- Specialization in Niche Market Recommended for Japanese Companies: Dr Bouee
September 23, 2002
- Toshiba: New Biochemical Analyzer ARCHITECT c8000
September 23, 2002
- BUSINESS NEWS IN BRIEF
September 23, 2002
- Takeda to Market Environmental Pollution Reagents via Biosense of Norway
September 23, 2002
- Female MRs Increasing: Education Center Report
September 23, 2002
- Kurabo Ties Up with Agilent Technologies for Contract Gene Analysis
September 23, 2002
- Generic Manufacturers Face Problems with Distribution
September 23, 2002
- Need for Spreading CAPD Stressed: Terumo Seminar
September 23, 2002
- Overseas Clinical Trials of Ono's Elaspol Suspended
September 23, 2002
- OTC NEWS IN BRIEF
September 23, 2002
- Daiichi to Restructure Global R&D System
September 23, 2002
- PRESS SEMINAR
September 23, 2002
- Taisho Toyama Pharm to Be Created Next Month
September 23, 2002
- Orthopaedic Associations Launch Campaign to Prevent Fractures
September 23, 2002
- Initial Sales of Bisphosphonate Disappointing
September 23, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 23, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…